Additionally, the correlation analysis results of the risk score and the clinical characteristics of 28 DOCK2 mutant samples revealed that there were no significant differences in risk scores, different ages, genders, clinical stages, and tumor stages (Figures 4C–F). The gene discussed is DOCK2; the disease is neoplasm.